FisnikuLKBrexPAAltmannDR. Disability and T2 MRI lesions: A 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain2008; 131: 808-817.
2.
ConfavreuxCVukusicSAdeleineP. Early clinical predictors and progression of irreversible disability in multiple sclerosis: An amnesic process. Brain2003; 126: 770-782.
3.
LerayEYaouanqJLe PageE. Evidence for a two-stage disability progression in multiple sclerosis. Brain2010; 133: 1900-1913.
4.
ScalfariANeuhausADegenhardtA. The natural history of multiple sclerosis: A geographically based study 10: Relapses and long-term disability. Brain2010; 133: 1914–1929.
5.
GoodinDSRederATEbersGC. Survival in MS: A randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial. Neurology2012; 78: 1315-1322.
6.
KapoorRFurbyJHaytonT. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: A randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol2010; 9: 681-688.
7.
LinkerRALeeDHRyanS. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain2011; 134: 678-692.
8.
GoldRKapposLArnoldDL. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med2012; 367: 1098-1107.
9.
FoxRJMillerDHPhillipsJT. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med2012; 367: 1087-1097.
10.
SühsKWHeinKSättlerMB. A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann Neurol2012; 72: 199-210.
11.
DiemRSattlerMBMerklerD. Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. Brain2005; 128: 375–385.
